Nevertheless, this work not only details novel determinants of eprenetapopt activity in cancer cells, including mito-1C metabolism enzymes, but also provides a clinical roadmap for targeting antioxidant pathways in tumors with eprenetapopt, beyond TP53-mutant tumors. Here, TP53 is linked to cancer.